Topische antiangiogene Therapie an der Hornhaut

Regenfuß, Birgit; Bock, Felix; Bachmann, Björn; König, Yanyan; Hos, Deniz; Parthasarathy, Anand; Cursiefen, Claus

doi:10.1007/s00347-009-1934-0

Cited by 15 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While this more targeted treatment avoids the side-effects of steroids, experimental and clinical studies have shown only a limited reduction in corneal neovessels. Using locally-applied anti-VEGF by topical 197 , subconjunctival 219 , intrastromal 220 , or intraocular route 221 , neovessel reduction in the range of 15-20 % in experimental studies 222 and of 36-61% in clinical studies 197,219,223 has been reported. Anti-VEGF may also have a shorter therapeutic window compared to steroids 159 .…”

Section: Anti-vegf Treatmentmentioning

confidence: 99%

Inhibitors of corneal inflammation and angiogenesis : Prospectives and challenges

Mirabelli

2019

Linköping University Medical Dissertations

View full text Add to dashboard Cite

row: photography of vessels in a cornea (false colours); computer elaboration of the vessels; HE histology of cornea with vessels and inflammatory cells; middle row: vessels and inflammatory cells seen with IVCM; lower row: HUVEC cells stained for VEGF; immunofluorescence of neovascularized cornea stained for CD31 and NFκB. Other illustrations in the thesis by Anthony Mukwaya, Per Lagman, Pierfrancesco Mirabelli. This thesis contains original material, and material reprinted from previously published work, published under a CC BY license (Creative Commons Attribution 4.0 International License), which allows for maximum dissemination and re-use of open access materials. IKE, Linköping university iv v …Instruction, and not silver; and Knowledge rather than choice gold. For Wisdom is better than rubies… (Proverbs 8: 10-11) vi vii ABSTRACT Pathologic angiogenesis is involved in cancer and several blinding conditions such as wet age-related macular degeneration, proliferative retinopathies and corneal neovascularization. In these dieseases, the angiogenic triggers are hypoxia and inflammation, and both involve the main angiogenic mediator, which is Vascular Endothelial Growth Factor (VEGF). Among available treatments, anti-VEGF often shows limited or temporary efficacy, while steroids are potentially responsible for many side-effects. This thesis presents a series of linked studies aimed at elucidating the early pathologic changes leading to inflammation and corneal neovascularization, and how various treatments affect this process. In this thesis, xii xiii LIST OF PUBLICATIONS INCLUDED IN THE THESIS PAPER I Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model. Mirabelli P, Peebo BB, Xeroudaki M, Koulikovska M, Lagali N. Exp Eye Res.

show abstract

Section: Anti-vegf Treatmentmentioning

confidence: 99%

Inhibitors of corneal inflammation and angiogenesis : Prospectives and challenges

Mirabelli

2019

Linköping University Medical Dissertations

View full text Add to dashboard Cite

show abstract

“…Vascular endothelial growth factor (VEGF) is thought to be one of the key mediators in the process of NV, and the effects of anti-VEGF antibodies have been demonstrated on various experimental corneal NV models (for review see Gupta and Illingworth 2011). So far, anti-VEGF antibodies have been licensed exclusively for vitreoretinal diseases, but they are off-label for corneal NV, as there is little evidence for their efficacy on the cornea (Regenfuss et al 2009; Benayoun et al 2012). …”

Section: Introductionmentioning

confidence: 99%

Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model

et al. 2013

View full text Add to dashboard Cite

The aim of this study is to determine the efficacy of a potent and specific vascular adhesive protein-1/ semicarbazide-sensitive amine oxidase (VAP-1/SSAO) inhibitor, LJP 1207, as a potential antiangiogenic and anti-inflammatory agent in the therapy of corneal neovascularization. Corneal neovascularization was induced with intrastromal suturing in rabbits (n = 20). Topical treatment with VAP-1/SSAO inhibitor LJP 1207 (n = 5, 4 times a day), bevacizumab (n = 5, daily), their combination (n = 5) and vehicle only (n = 5, 4 times a day) were applied postoperatively for 2 weeks. The development and extent of corneal neovascularization were evaluated by digital image analysis. At the end of the observation period, the level of corneal and serum VAP-1/SSAO activity was measured fluorometrically and radiochemically. The corneal VAP-1/SSAO activity was significantly elevated in the suture-challenged vehicle-treated group (3,075 ± 1,009 pmol/mg/h) as compared to unoperated controls (464.2 ± 135 pmol/mg/h, p <0.001). Treatment with LJP 1207 resulted in slower early phase neovascularization compared to vehicle-treated animals (not significant). At days 7–14, there was no significant difference in the extent of corneal neovascularization between inhibitor- and vehicle-treated corneas, even though inhibitor treatment caused a normalization of corneal VAP-1/SSAO activity (885 ± 452 pmol/mg/h). Our results demonstrate that the significant elevation of VAP-1/SSAO activity due to corneal injury can be prevented with VAP-1/SSAO inhibitor LJP 1207 treatment. However, normalization of VAP-1/ SSAO activity in this model does not prevent the development of corneal neovascularization.

show abstract

Einführung

Assadian

Bialasiewicz

Falke

et al. 2014

Entzündliche Augenerkrankungen

View full text Add to dashboard Cite

show abstract

Topische antiangiogene Therapie an der Hornhaut

Abstract: Avastin and GS101 eye drops are the first specific angiogenesis inhibitors for topical inhibition of corneal angiogenesis available for clinical use.

Cited by 15 publications

References 27 publications

Inhibitors of corneal inflammation and angiogenesis : Prospectives and challenges

Inhibitors of corneal inflammation and angiogenesis : Prospectives and challenges

Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model

Einführung

Contact Info

Product

Resources

About